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Background: There is a risk of drug sorption into an intravenous administration set composed of polyvinyl chloride (PVC),
polyurethane (PU), or polyoleﬁn (PO). This has implications on the dose of the active ingredient the patient receives, and thus
therapeutic success. This study aimed to determine the plasma concentration of nitroglycerin and the effect of nitroglycerin on
patients based on the composition of the administration set.
Methods: Using a randomized, open-labeled, 33 crossover method, 9 volunteers were assigned to 3 groups. In period I,
nitroglycerin (100mg/mL) was infused via a PVC- (group A), PU- (group B), or PO-based (group C) administration set. In period II, PU-
(group A), PO- (group B), and PVC-based (group C) administration sets were used, and in period III, PO- (group A), PVC- (group B),
and PU-based (group C) administration sets were used. The rate of drug administration in all periods was 12mL/hour for 30minutes
using an infusion pump. Blood samples were collected, and the plasma concentrations of nitroglycerin were analyzed using validated
high-performance liquid chromatography coupled with tandem mass spectrometry. Blood pressure was determined using a
sphygmomanometer applied to the other upper arm at an interval of 5minutes.
Results:We observed that the mean plasma concentration of nitroglycerin over time when administered using a PO-based tube
was higher than that when using a PU- or PVC-based tube. When the percent change of the mean arterial pressure from baseline at
each time point was compared among groups, there were statistically signiﬁcant differences between PU and PO or PVC at most
points during nitroglycerin infusion.
Conclusion: Our results showed higher nitroglycerin plasma concentration and lower arterial pressure when a PO-based
administration set was used than when a PVC- or PU-based administration set was used. PO-based administration sets may be
more appropriate for nitroglycerin administration compared to those composed of PVC or PU.
Abbreviations: AEs = adverse events, EKG = electrocardiography, HPLC = high-performance liquid chromatography, MAP =
mean arterial pressure, PK = pharmacokinetics, PO = polyoleﬁn, PU = polyurethane, PVC = polyvinyl chloride.
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The risk of drug sorption into the administration set has beenwell
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1patients by preventing them from receiving the physician-
intended drug dosage. Nitroglycerin is a nitrate used for
vasodilation in patients with hypertension and ischemic heart
disease.[4] Sorption of nitroglycerin into the administration set
can increase the risk of cardiovascular instability due to the
administration of an inadequate dosage. In previous studies, the
possibility of nitroglycerin sorption into administration set tubes
composed of polyvinyl chloride (PVC), polyurethane (PU), or
polyoleﬁn (PO) has been discussed.[5,6] Park et al[7] showed PO
administration set prohibited drug sorption when compared to
the PVC and PU administration set; however, these were in vitro
studies. Altavela et al[8] also revealed that patients who received
intravenous nitroglycerin through a PVC administration set had
the same clinical response as patients given the drug through a
polyethylene set. There is a paucity of in vivo studies focused on
the plasma concentration and efﬁcacy of drugs comparing PO,
PU, and PVC administration sets. As individual variation among
patients can affect sensitivity to drugs, and this could in turn
inﬂuence therapeutic outcomes, we cannot ascertain whether
drug sorption into the administration set contributes to differ-
ences in a drug’s effect. Moreover, the clinical environment is
Table 1
The summary of the intervention cycle.
Group Period I WP, d Period II WP, d Period III
A PVC 5 PU 5 PO
B PU 5 PO 5 PVC
Kim et al. Medicine (2018) 97:9 Medicinedifferent from that of a laboratory in terms of the total length of
the intravenous set, means of connecting the set, and drug
infusion rate. The present study aimed to explore the effect of the
composition of the administration set on the plasma concentra-
tion and effect of nitroglycerin on patients.C PO 5 PVC 5 PU
PO=polyoleﬁn, PU=polyurethane, PVC=polyvinylchloride, WP=washout period.
2. Methods
2.1. Chemicals
We used 3 different types of administration sets with tubes
composed of PVC, PU, and PO. Di-(2-ethylhexyl) terephthalate
(DEHT) was used as the plasticizer for the PVC tube. All tubes
had a length of 100cm, and were manufactured and supplied by
Polyscientech Co., Ltd (Anseong, Gyeonggi, Korea). An
independent experimenter diluted nitroglycerin (Bayer Pharma
AG, Leverkusen, Germany) with 90mL of normal saline to
obtain a ﬁnal concentration of 100mg/mL.2.2. Patients
The Severance Hospital Institutional Review Board provided
ethics approval for this study; we obtained written informed
consent from all study participants. All volunteers were men,
aged 19 to 50 years, with a BMI of 18.5 to 25kg/m2. A complete
medical history of all participants was obtained, and all of them
underwent comprehensive physical screening and examination,
EKG (electrocardiography), and laboratory tests. Exclusion
criteria were as follows: a history of abnormalities of the
cardiovascular, respiratory, renal, endocrinal, hepatic, hemato-
logic, or gastrointestinal system or any other signiﬁcant disease
state that could affect pharmacokinetics (PK); drug addiction,
including opioids, narcotics, or any other drugs, affecting the
central nervous system; chronic use of any medication; and
hypersensitivity to nitroglycerin or any other nitrate drugs. Nine
volunteers were recruited to take part in the present study. The
present study was a randomized, open-labeled, 33 crossover
study; therefore, 3 volunteers each were randomly allocated to
groups A, B, and C. In group A, a PVC-based tube was used in
period I, and PU- and PO-based tubes were used in periods II and
III, respectively. In group B, PU-, PO-, and PVC-based tubes were
used in periods I, II, and III, respectively, and in group C, PO-,
PVC-, and PU-based tubes were used in periods I, II, and III,
respectively.
2.2.1. Period I.On day 1, all volunteers fasted for 4hours before
arriving at the hospital. Water intake was restricted for an hour
before and after the administration of nitroglycerin. Patients were
subjected to EKG, noninvasive blood pressure monitoring, and
pulse oximetry. A 23-gauge intravenous catheter was inserted
into the forearm vein. Blood pressure was determined using an
upper-arm sphygmomanometer at an interval of 5minutes. The
100-cm-long administration set tube was connected to the
catheter. Following predosing blood sample collection, nitro-
glycerin (100mg/mL) was infused via PVC (group A)-, PU (group
B)-, or PO (group C)-based tubes at the rate of 12mL/hour for 30
minutes by using an infusion pump. Blood samples were collected
at 2, 5, 10, 20, and 30minutes after administration was initiated
and at 3, 6, and 10minutes after drug administration completed.
A blood sample of 5mL was transferred to an EDTA-containing
tube and centrifuged within an hour after collection. The
centrifuged plasma samples were placed on ice until they were
transported to the laboratory for storage at 70°C. The plasma
concentration of nitroglycerin was obtained from the laboratory2within a month. Blood pressure and heart rate were recorded
before administration and at 2, 4, 6, 8, 10, 14, 18, 22, 26, and 30
minutes after drug administration was initiated and at 4, 8, 12,
16, 20, 24, 28, and 32minutes after drug administration was
completed.
2.2.2. Periods II and III. As there was a washout interval, period
II was started 5 days or more after period I was concluded. The
protocol used in period II for drug administrationwas the same as
that in period I, except for the type of administration tube used in
each group. Similarly, period III was initiated 5 days ormore after
period II was concluded. The summary of the intervention cycle is
outlined in Table 1.2.3. Plasma nitroglycerin assay
The plasma concentrations of nitroglycerin were analyzed using
validated high-performance liquid chromatography (HPLC,
Agilent 1200 HPLC system; Agilent Technologies, Santa Clara,
CA) coupled with tandem mass spectrometry (MS/MS,
4000Qtarp; ABSICX, Concord, Ontario, Canada). The analytical
columnwas a Kinetex C18 (1004.6mm, 2.6mm) (Phenomenex,
Torrance, CA), and the mobile phase comprised solvent A (0.025
mM ammonium chloride) and solvent B (methanol). The
separation method used was a gradient method. The organic
solvent used was initially of low concentration (5% Solvent B),
which was increased (95% Solvent B), and then decreased to the
initial concentration (5%SolventB).The total analysis timewas15
minutes; the ﬂow rate was 550mL/min. The working solutions of
nitroglycerin were prepared at human plasma concentrations of
0.1 – 50.0ng/mL. The sample was prepared as follows: an aliquot
of 500mL of human plasma was transferred to a polypropylene
tube; 1000mL of acetonitrile and the internal standard solution
were added; and the mixture was vortex-mixed for a minute. The
sample was centrifuged at 13,000rpm for 10minutes, and the
supernatant was separated. A sample (15mL) of the supernatant
was then injected into an LC-MS/MS system. The concentrations
of nitroglycerin were calculated from the calibration curve. The
calibration standards showed acceptable linearity (correlation
coefﬁcient, r2>0.99) over a concentration range of 0.1 to 50.0ng/
mL, determined by a 1/x2 weighted least-squares linear regression
analysis. The precision of the assay was less than 20%, and the
accuracy was within the range of 80% to 120%.2.4. PK analysis
The PK parameters of nitroglycerin were calculated via non-
compartmental analysis using Phoenix 64 WinNonlin 7.0
software (Pharsight, Mountain View, CA). The maximum
plasma concentration (Cmax) and the time to reach the Cmax
(tmax) were determined directly from the observed data. The area
under the plasma concentration–time curve from dosing time (0
hour) to the time of the last measurable concentration (AUClast)
was calculated using the linear trapezoidal rule. Most of the
Kim et al. Medicine (2018) 97:9 www.md-journal.comsamples collected after the infusion of nitroglycerin were below
the limit of quantiﬁcation, and the terminal elimination rate
constant (lz), elimination half-life (t1/2), and the plasma clearance
could not be calculated.2.5. Safety assessment
Safety was assessed via physical examinations and by monitoring
vital signs (systolic blood pressure, diastolic blood pressure, pulse
rate, and body temperature), 12-lead ECG, and laboratory tests
at predeﬁned time points. In addition, adverse events (AEs) were
evaluated throughout the study. Any undesirable sign, symptom,
or medical condition occurring after the administration of the
study drug was recorded, regardless of its suspected relationship
to the study medication.2.6. Statistical analysis
The PK data were analyzed and compared among the 3
administration sets (PO, PU, and PVC). All data are expressed
as mean± standard deviation (SD). The primary PK parameters
(Cmax andAUClast) were log-transformedandanalyzed by analysisFigure 1. Stud
3of variance (ANOVA) using a mixed-effects model. To compare
the PK parameters, point estimates and 90% conﬁdence intervals
(CI) for the geometricmean ratios (PU/POandPVC/PO) of the log-
transformedCmax and AUClast were also calculated. The repeated-
measuresmixedmodelwasapplied to compare thepercent changes
in mean arterial pressure (MAP, MAP= [SBP+2DBP]/3) from
baseline among the 3 administration set groups. The baselineMAP
as a covariate and the administration set, time, period, sequence,
and time-to-administration set interactions were analyzed as ﬁxed
effects. The demographic characteristics were analyzed using the
Kruskal–Wallis test for comparison among the 3 sequences (A, B,
andC). All analyses were conducted using SAS statistical software,
version 9.2 (SAS Institute, Inc., Cary, NC). All statistical tests were
2-sided, and statistical signiﬁcance was deﬁned as P< .05.3. Results
3.1. Study participants
The progression of participants through the study is illustrated in
Fig. 1. A total of 9 healthy Korean male participants were
enrolled. Three participants were randomly assigned to eachy ﬂow chart.
Table 2
Demographics and baseline characteristics of the study population.
A (n=3) B (n=3) C (n=3) Total (n=9)
Age, y 33.3±10.2 (26.0–45.0) 36.3±7.6 (31.0–45.0) 29.7±2.1 (28.0–32.0) 33.1±7.1 (26.0–45.0)
Body weight, kg 70.0±10.9 (62.3–82.5) 71.8±6.1 (66.6–78.6) 76.1±8.7 (69.4–85.9) 72.7±8.1 (62.3–85.9)
Body mass index, kg/m2 22.6±1.1 (21.5–23.6) 23.1±1.8 (21.0–24.2) 22.9±0.7 (22.1–23.4) 22.9±1.1 (21.0–24.2)
Notes: The data are expressed as mean±SD (min–max).
In Group A, the sequence of drug administration using different administration sets was PVC (polyvinylchloride)–PU (polyurethane)–PO (polyoleﬁn); in group B, the sequence was PU–PO–PVC; and in Group C, the
sequence was PO–PVC–PU.
All subjects received intravenous infusions of nitroglycerin during each set of infusions; there was a washout period of at least 5 days between each set of infusions.
The P values of the 3 groups were calculated using the Kruskal–Wallis test. There were no statistically signiﬁcant differences in age, body weight, and body mass index among the 3 groups.
Kim et al. Medicine (2018) 97:9 Medicineadministration set sequence group. One participant in C group
experienced syncope during nitroglycerin infusion with the PO
administration set and was excluded from the study. All the other
subjects completed the study. The participants in each sequence
group were administered nitroglycerin intravenously for 30
minutes in the following sequence: PVC–PU–PO (A group), PU–
PO–PVC (B group), and PO–PVC–PU (C group). There were no
statistically signiﬁcant differences in age, body weight, or body
mass index among the sequence groups (P> .05, Table 2).Figure 2. Mean plasma nitroglycerin concentration–time proﬁles after intravenou
scale). PO=polyoleﬁn, PU=polyurethane, PVC=polyvinylchloride.
43.2. PK parameters
The PK parameters were analyzed using data from the 8 subjects
who completed this study. In all administration sets, plasma
concentration of nitroglycerin increased rapidly after IV infusion
and reached steady state after approximately 5minutes (Fig. 2).
When nitroglycerin was infused with the PO administration set,
the mean plasma concentration of nitroglycerin over time was
higher than that in the PU or PVC administration set group. The
calculated PK parameters of nitroglycerin are shown in Table 3.s infusion in healthy male subjects (upper: linear scale, lower: semilogarithmic
Table 3
Pharmacokinetic parameters of nitroglycerin after intravenous infusion in healthy volunteers according to the administration set (n=8).
PK parameters Geometric mean ratio (90% CI)
PO PU PVC PU/PO PVC/PO
Cmax, ng/mL 1.37±0.89 0.17±0.18 0.33±0.19 0.21 (0.07–0.65) 0.33 (0.17–0.65)
AUClast, min ng/mL 36.17±25.54 1.78±1.72 6.94±4.25 0.09 (0.03–0.27) 0.26 (0.13–0.51)
tmax, min 23.5 (10.0–39.0) 20.0 (9.0–24.0) 10.0 (8.0–24.0) — —
Notes: The values are presented as mean±SD, except for tmax, which is presented as median (range).
AUClast= area under the plasma concentration–time curve from dosing time (0 hour) to the time of the last measurable concentration, CI= conﬁdence interval, Cmax=maximum plasma concentration of the
nitroglycerin, PK=pharmacokinetic, PO=polyoleﬁn, PU=polyurethane, PVC=polyvinylchloride, tmax= time to Cmax.
Kim et al. Medicine (2018) 97:9 www.md-journal.comThe Cmax and AUClast of nitroglycerin in the PO or PVC
administration set group were compared with those in the PU
administration set group. When Cmax and AUClast of nitroglyc-
erin in the PU administration set groupwere comparedwith those
in the PO administration set group, the point estimates (with
90% CI) of the geometric mean ratios were 0.21 (0.07–0.65) and
0.14 (0.05–0.46), respectively. When Cmax and AUClast of
nitroglycerin in the PVC administration set group were compared
with those of the PO administration set group, the point estimates
(with 90% CI) of the geometric mean ratios were 0.33 (0.17–
0.65) and 0.31 (0.15–0.64), respectively.
3.3. Blood pressure
Blood pressure of all but the one participant who was excluded
was analyzed. When the percent change of MAP from baseline in
each time point was compared among administration set groups,
there were statistically signiﬁcant differences between PU and PO
or PVC administration set groups at most points during
nitroglycerin infusion (P< .05, Fig. 3). There was no statistically
signiﬁcant difference between the PO and the PVC administration
set groups in percentage change of MAP from baseline, except at
the end of infusion.
3.4. Safety
There were 2 AEs in total, and they were considered related to the
administration of nitroglycerin (Table 4). The ﬁrst AE occurred
during the infusion of nitroglycerin with the PO administration
set; the subject developed a mild headache for 3minutes, which
resolved. This incidence did not occur in the other administration
set groups. The second AE was syncope, which also occurred in
the PO administration set group. In this case, blood pressure
dropped rapidly right after the infusion of nitroglycerin, and the
subject became unconscious for approximately 2seconds. The
subject recovered without any complications but was excluded
from the study as a safety precaution. There were no life-
threatening drug-induced AEs reported in this study.4. Discussion
The material nature of a drug carrier can affect the delivery and
effect of the drug. The sorption of a number of drugs from
solutions by plastic bags was investigated.[9] The developing drug
carriers that facilitate the sustained and long-term release of drugs
and improve the pharmacological bioavailability is an important
issue.[10,11] The material of an administration set can also
inﬂuence on the effect of the drug.[1,2]
We performed a preliminary study to explore the effect of the
materials used in different drug administration sets—namely,
PVC, PU, and PO—on the PK and pharmacodynamic proﬁle of5nitroglycerin by comparing the plasma concentration and
efﬁcacy of nitroglycerin in the same subject. The Cmax, AUClast,
and the effect of nitroglycerin on blood pressure decreased when
PVC- and PU-based administration sets were used compared to
those when the PO-based administration sets were used. This
may be due to the sorption of nitroglycerin into the PVC- and PU-
based administration sets.
Previous in vitro studies reported that the percentage sorption
of nitroglycerin in PVC-based administration sets to be
approximately 18% to 43% depending on the physiological
condition.[6] Nitroglycerin, however, has high intersubject
pharmacokinetic variability, because it has extensive tissue
distribution and rapid plasma clearance.[4] Unfortunately,
previous studies did not conﬁrm whether the sorption of
nitroglycerin into the administration sets made of different
materials induced any clinically signiﬁcant effect on the plasma
concentration of nitroglycerin and blood pressure in patients.
Thus, clinical studies such as the present study were required.
Our results showed that the mean plasma concentration of
nitroglycerin in the PO administration set group over time was
higher than those in the PU or PVC administration set group.
These ﬁndings are in agreement with those of prior studies,[9,12–
14] suggesting that the tube material inﬂuences the nitroglycerin
concentration due to drug sorption. This phenomenon can be
explained by several theories. First, partitioning of drugs between
the polymer and contact media is related to their hydrophobic-
ity.[15] Equilibrium of a drug between the tube material and the
injectable media is affected by its partition coefﬁcient, which is a
major factor in drug sorption in the administration set. Drug
sorption is also affected by the structure-based polarity and
molecular weight of the polymers used in administration sets.[16]
Additionally, plasticizers may leach from a PVC-based tube, and
the leaching of chemicals from the administration set can lead to a
decrease in drug concentration.[17–19]
We also observed that the Cmax and AUClast of the PO group
were higher than those of PVC and PU groups. These results
indicated that the PO-based administration set could minimize
the sorption of nitroglycerin into the tube. The possible
explanation is that PO has a lower partition coefﬁcient than
does PVC or PU; therefore, a multicomponent polymer matrix
(polyethylene elastomer, polypropylene elastomer, polybutadi-
ene blend) of PO tubes can be equilibrated with reduced drug loss
compared to PVC- and PU-based administration sets.[20]
In the present study, we noted that there were signiﬁcant
differences in lowering mean arterial pressure among the 3 types
of tubes. The PO-based tube showed a more signiﬁcant
hypotensive effect than PU- and PVC-based tubes. The
nitroglycerin acting on peripheral veins decreases venous return,
resulting in a decrease in end-diastolic volume and pressure by the
LaPlace relationship, and thus a decrease in myocardial oxygen
consumption.[21–23] The nitroglycerin also acts as a vasodilator of
Figure 3. Mean (±standard deviation) arterial blood pressure after intravenous drug infusion in healthy male subjects. The marks mean P< .05, as compared
between the PU and PO groups (∗), between the PU and PVC (†), and between the PO and PVC (∗∗) according to changes from baseline, by the repeated-measures
mixed model. MAP=mean arterial pressure, PO=polyoleﬁn, PU=polyurethane, PVC=polyvinylchloride.
Kim et al. Medicine (2018) 97:9 Medicineperipheral arteries. The decrease in mean arterial pressure would
be expected to result in a further decrease in myocardial wall
tension and an improvement in ventricular function.[24,25] The
administration of nitroglycerin intravenously through the PO-
based tube may therefore allow more precise control of dosage
and help avoid reduction in efﬁcacy.
In this study, nitroglycerin was diluted to 100mg/mL and
infused at a rate of 12mL/hour (20mg/min) through a 100-cmTable 4
Incidence of adverse events per administration set.
System organ class/preferred term PO PU PVC
Nervous system disorders
Headache 1 (11.1) – –
Vascular disorders
Syncope 1 (11.1) – –
Note: The data are expressed as the number (%) of adverse events.
PO=polyoleﬁn, PU=polyurethane, PVC=polyvinylchloride.
6tube, as per a recommended guideline for nitroglycerin
infusion.[4,8] Moreover, several studies revealed that as ﬂow
rate decreased or tube length increased, the amount of drug
absorbed increased proportionately.[26,27] Thus, caution should
be exercised when applying our result to a different clinical
setting.
There are several limitations to the present study. First, we did
not measure the concentration of nitroglycerin in the tube. It is
reasonable to assume, however, that sorption of nitroglycerin
into the tube caused the difference in plasma nitroglycerin
concentration and arterial pressure, according to the types of
materials used in the tubes, as several in vitro studies on sorption
of nitroglycerin into the tube have been carried out.[5,6] A
sampling of drug from the administration set can also interfere in
measuring the plasma concentration and the effect of the drug.
Second, we had a small sample size (9 volunteers). This study is
preliminary; thus, further investigation with a larger sample size
should be conducted in future. Third, we did not estimate the
terminal elimination rate constant (lz), elimination half-life (t1/2),
[11] Lee C-H, Li Y-J, Huang C-C, et al. Poly(e-caprolactone) nanocapsule
Kim et al. Medicine (2018) 97:9 www.md-journal.comor plasma drug clearance, because most of the samples collected
after infusion of nitroglycerin were determined to be below the
limit of quantiﬁcation.
In conclusion, healthy volunteers administered intravenous
nitroglycerin via a PO-based tube had higher plasma
concentrations of nitroglycerin and more signiﬁcant reduc-
tions in blood pressure than those who received nitroglycerin
through PVC- or PU-based tubes. This result suggests that the
sorption of nitroglycerin is less in the PO-based tube than in
the PVC- or PU-based tube, indicating that the tube materials
used for drug administration may play a critical role in drug
efﬁcacy and safety.References
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